Chiusura precedente | 1,3700 |
Aperto | 1,3200 |
Denaro | 1,3700 x 600 |
Lettera | 1,4600 x 600 |
Min-Max giorno | 1,3200 - 1,4700 |
Intervallo di 52 settimane | 0,5900 - 2,3100 |
Volume | |
Media Volume | 1.640.885 |
Capitalizzazione | 177,932M |
Beta (5 anni mensile) | 1,24 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,2400 |
Prossima data utili | 13 mag 2024 - 17 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 4,58 |
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023. Details of the company's participation are as follows: Cantor Fitzgerald Global Healthcare Conference 2023Format: Fireside Chat with
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver as Chief Financial OfficerEnded second quarter 2023 with $99.4 million of cash and cash equivalents SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unme
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023. Second Quarter 2023 Conference Cal